RayKnowChina Research Map
Shortlist

ShijiazhuangHebei Medical University

Second Hospital of Hebei Medical University

河北医科大学第二医院

Listed for 23 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Hospital of Hebei Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌5 papers led
  2. Stomach cancer胃癌23 papers led
  3. Osteosarcoma骨肉瘤0 papers led
  4. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  5. Neuroblastoma神经母细胞瘤6 papers led
  6. Ewing sarcoma尤文肉瘤0 papers led
  7. Multiple myeloma多发性骨髓瘤3 papers led
  8. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  9. Haemophilia A血友病 A0 papers led
  10. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  11. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病16 papers led
  12. Moyamoya disease烟雾病2 papers led
  13. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  14. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  15. Amyotrophic lateral sclerosis肌萎缩侧索硬化症19 papers led
  16. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  17. Fabry disease法布雷病2 papers led
  18. Duchenne muscular dystrophy杜氏肌营养不良4 papers led
  19. Behçet disease白塞病0 papers led
  20. IgA nephropathyIgA 肾病2 papers led
  21. Gaucher disease戈谢病0 papers led
  22. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  23. Hirschsprung disease先天性巨结肠1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, IgG4-related disease, Myasthenia gravis, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Pompe disease, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 5 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 2220242025: 002025

5 hospitals in Shijiazhuang for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapy
Departments in papersGastroenterology / hepatologyMedical oncology
Papers it led5
  1. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.2024Expert review of pharmacoeconomics & outcomes research
  2. Innovative prognostic modeling in ESCC: leveraging scRNA-seq and bulk-RNA for dendritic cell heterogeneity analysis.2024Frontiers in immunologyFree full text
  3. A novel and robust pyroptosis-related prognostic signature predicts prognosis and response to immunotherapy in esophageal squamous cell carcinoma.2023AgingFree full text
  4. CCT6A promotes esophageal squamous cell carcinoma cell proliferation, invasion and epithelial-mesenchymal transition by activating TGF-β/Smad/c-Myc pathway.2023Irish journal of medical science
  5. Exploring the Potential of Exosome-Related LncRNA Pairs as Predictors for Immune Microenvironment, Survival Outcome, and Microbiotain Landscape in Esophageal Squamous Cell Carcinoma.2022Frontiers in immunologyFree full text
More papers found outside PubMed (not counted)4
  1. Risk factors of sarcopenia in patients with esophageal squamous cell carcinoma2024Research Squarepreprint
  2. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  3. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  4. Corrigendum: Contrast-Enhanced CT-Based Radiomics Analysis in Predicting Lymphovascular Invasion in Esophageal Squamous Cell Carcinoma2021Frontiers in Oncologyerratum

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 23 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
23
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 2220222023: 7720232024: 3320242025: 442025

5 hospitals in Shijiazhuang for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapy & targeted drugsChemotherapy & combined treatmentPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologyMedical oncologySurgery (general/hepatobiliary/pancreatic)Neurology
Papers it led23
  1. Diagnostic value of SSTR2A, ATRX, and clusterin immunohistochemical expression in high-grade gastroenteropancreatic neuroendocrine neoplasms.2026Annals of diagnostic pathology
  2. Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models.2025Acta oncologica (Stockholm, Sweden)Free full text
  3. Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger.2025Anti-cancer agents in medicinal chemistry
  4. Value of endoscopic submucosal dissection in diagnosing gastric mucosa-associated lymphoid tissue lymphoma: A case report.2025World journal of gastroenterologyFree full text
  5. miR-1287-5p suppresses proliferation, migration, invasion and promotes apoptosis in gastric cancer cells through targeting LAMTOR3.2025World journal of surgical oncologyFree full text
  6. Knowledge and practice of early gastric cancer screening among adults aged ≥ 45 years in China: a cross-sectional study.2024BMC public healthFree full text
  7. Public awareness of gastric cancer risk factors and screening behaviours in Shijiazhuang, China: A community-based survey.2024PloS oneFree full text
  8. Identification of Immune Infiltrating Cell-Related Biomarkers in Early Gastric Cancer Progression.2024Technology in cancer research & treatmentFree full text
  9. Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer.2023BMC gastroenterologyFree full text
  10. COL5A2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer based on transcriptomics and single-cell RNA sequencing.2023BMC medical genomicsFree full text
  11. Preoperative monocyte to high-density lipoprotein ratio as a predictor of survival outcome of gastric cancer patients after radical resection.2023Biomarkers in medicine
  12. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.2023Journal of cancer research and clinical oncologyFree full text
  13. Cuproptosis-related gene SERPINE1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  14. Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer.2023Journal of translational medicineFree full text
  15. Integrated analysis identities Rho GTPases related molecular map in patients with gastric carcinoma.2023Scientific reportsFree full text
  16. LncRNA TNFRSF10A-AS1 promotes gastric cancer by directly binding to oncogenic MPZL1 and is associated with patient outcome.2022International journal of biological sciencesFree full text
  17. The current management and biomarkers of immunotherapy in advanced gastric cancer.2022MedicineFree full text
  18. The Effect of Pancreatoduodenectomy Plus Intraperitoneal Hyperthermic Perfusion on Resectable Pancreatic Head Cancer: Cohort Study.2021Annals of surgical oncology
  19. Co-expression of VEGF-B and FLT-1 correlates with malignancy and prognosis of gastric cancer.2021Biomarkers in medicine
  20. Circ_0027599 elevates RUNX1 expression via sponging miR-21-5p on gastric cancer progression.2021European journal of clinical investigation
  21. Toothbrushing frequency and gastric and upper aerodigestive tract cancer risk: A meta-analysis.2021European journal of clinical investigation
  22. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.2021MedicineFree full text
  23. Comparative analysis of laparoscopic proximal gastrectomy plus semi-embedded valve anastomosis with laparoscopic total gastrectomy for adenocarcinoma of the esophagogastric junction: a single-center retrospective cohort study.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Shijiazhuang for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors in Bronchus.2019The American journal of the medical sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Shijiazhuang for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 6 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 1120242025: 112025

4 hospitals in Shijiazhuang for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shijiazhuang for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors in Bronchus.2019The American journal of the medical sciences

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

4 hospitals in Shijiazhuang for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    68Ga-BCMA PET/CT in Multiple Myeloma
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Registry
    NCT07319897

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Changchun, Shijiazhuang

  3. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  4. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  5. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskCAR-T & cell therapyStem cell transplant
Papers it led3
  1. Investigating the role of tumor cell heterogeneity and angiogenesis genes in the prognosis of multiple myeloma.2025Frontiers in immunologyFree full text
  2. Small intestinal angiodysplasia and hemorrhage associated with acquired von Willebrand syndrome type 2A secondary to multiple myeloma: Reversal after treatment with IRD regimen (a case report and a brief review of the literature).2024Thrombosis research
  3. Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma.2024Transplantation and cellular therapy
Chinese-language papers (not in the count)2
  1. [Inhibitory Effect of Resveratrol on the Proliferation of Multiple Myeloma Cells and the Underlying Mechanism].2023Zhongguo shi yan xue ye xue za zhi
  2. [MiR-21 Regulates the Proliferation of Multiple Myeloma Cells by Inhibiting the Expression of KLF5].2022Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status6
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Study sitePhase 2/Phase 3Start 2025-12
  4. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  5. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  6. CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04626752Study siteEarly phase 1Start 2020-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Shijiazhuang for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesTreatment regimensStem cell transplantGenetics & inherited forms

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Shijiazhuang for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Clinical Analysis of 25 Cases of Acquired Hemophilia A in a Single Center].2024Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shijiazhuang for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 16 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 3.3%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 4420232024: 5520242025: 332025

2 hospitals in Shijiazhuang for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAcute attack treatmentAntibodies & diagnosisRelapse prevention
Departments in papersNeurology
Papers it led16
  1. Let-7f-5p/AIMP1/ZO-1 axis mediates blood-brain barrier dysfunction in neuromyelitis optica spectrum disorders.2025Clinical and experimental immunology
  2. Alterations in peripheral blood immune cell profiles of neuromyelitis optica spectrum disorder across different phases and after B cell depletion therapy.2025Frontiers in immunologyFree full text
  3. BTK and YKL-40 Levels and Their Association with Acute AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.2025Molecular neurobiology
  4. Association of plasma sPD-1 and sPD-L1 with disease status and future relapse in AQP4-IgG (+) NMOSD.2024Annals of clinical and translational neurologyFree full text
  5. Reduced serum IgG galactosylation is associated with increased inflammation during relapses of neuromyelitis optica spectrum disorders.2024Frontiers in immunologyFree full text
  6. Interferon Regulatory Factor 5 Gene Polymorphisms and mRNA Expression Levels Are Associated with Neuromyelitis Optica Spectrum Disorder.2024Molecular neurobiology
  7. Deciphering prognostic indicators in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: An integrative review of demographic and laboratory factors.2024Multiple sclerosis (Houndmills, Basingstoke, England)
  8. Combined platelet-to-lymphocyte ratio and blood-brain barrier biomarkers as indicators of disability in acute neuromyelitis optica spectrum disorder.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Decreased SIRT1 mRNA expression in peripheral blood mononuclear cells from patients with neuromyelitis optica spectrum disorders.2023Acta neurologica Belgica
  10. Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.2023Cellular and molecular neurobiologyFree full text
  11. Downregulation of lncRNA XIST may promote Th17 differentiation through KDM6A-TSAd pathway in neuromyelitis optica spectrum disorders.2023Multiple sclerosis and related disorders
  12. Secreted aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) is a promising predictor for the severity of acute AQP4-IgG positive neuromyelitis optica spectrum disorder.2023Multiple sclerosis and related disorders
  13. Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders.2022European journal of medical researchFree full text
  14. Altered non-coding RNA profiles and potential disease marker identification in peripheral blood mononuclear cells of patients with NMOSD.2022International immunopharmacology
  15. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  16. BLK polymorphisms and expression level in neuromyelitis optica spectrum disorder.2021CNS neuroscience & therapeuticsFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
More papers found outside PubMed (not counted)1
  1. LncRNA Xist may regulate Th17 cell differentiation through TDP43-IRF3 pathway in neuromyelitis optica spectrum disorders2022Medical Hypothesesarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Shijiazhuang for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStroke & bleeding outcomesRevascularisation surgeryImaging & blood flow
Departments in papersNeurosurgeryNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Shijiazhuang for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

4 hospitals in Shijiazhuang for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 19 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 2.4%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 0020222023: 4420232024: 7720242025: 442025

2 hospitals in Shijiazhuang for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Papers it led19
  1. m6A Methylation-Induced Autophagy Impairment by TFEB Regulation in SOD1-G93A ALS Cell Model.2025American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  2. Stage-dependent efficacy of short-chain fatty acids in amyotrophic lateral sclerosis: Insights into autophagy and neuroprotection.2025Life sciences
  3. Myeloid Irf5 Deficiency Enhances the Therapeutic Efficacy of IMD-0354 in a TDP-25-Induced Neurodegeneration Model.2025Molecular neurobiology
  4. Microglial upregulation of CD109 expression in spinal cord of amyotrophic lateral sclerosis mouse model and its role in modulating inflammation and TGFβ/SMAD pathway.2025Neuroscience
  5. The Beaumont behavioral intervention in a Chinese amyotrophic lateral sclerosis cohort.2024Amyotrophic lateral sclerosis & frontotemporal degeneration
  6. Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.2024Amyotrophic lateral sclerosis & frontotemporal degeneration
  7. Inhibiting NF-κB inducing kinase improved the motor performance of ALS animal model.2024Brain research
  8. RABGGTB plays a critical role in ALS pathogenesis.2024Brain research bulletin
  9. Neuroprotective Effect of a Multistrain Probiotic Mixture in SOD1G93A Mice by Reducing SOD1 Aggregation and Targeting the Microbiota-Gut-Brain Axis.2024Molecular neurobiology
  10. Cortical structure and the risk of amyotrophic lateral sclerosis: A bidirectional Mendelian randomization study.2024Progress in neuro-psychopharmacology & biological psychiatry
  11. OPTN gene therapy increases autophagy and protects mitochondria in SOD1-G93A-expressing transgenic mice and cells.2024The FEBS journal
  12. IRF5 knockdown reverses TDP-related phenotypes partially by increasing TBK1 expression.2023Brain research
  13. scAAV9-VEGF alleviates symptoms of amyotrophic lateral sclerosis (ALS) mice through regulating aromatase.2023Experimental brain research
  14. Proteomics analysis indicates the involvement of immunity and inflammation in the onset stage of SOD1-G93A mouse model of ALS.2023Journal of proteomics
  15. Sleep disorders and white matter integrity in patients with sporadic amyotrophic lateral sclerosis.2023Sleep medicine
  16. Simvastatin accelerated motoneurons death in SOD1G93A mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles.2021Cell death & disease
  17. Myeloid TBK1 Deficiency Induces Motor Deficits and Axon Degeneration Through Inflammatory Cell Infiltration.2021Molecular neurobiology
  18. Oxymatrine Extends Survival by Attenuating Neuroinflammation in a Mouse Model of Amyotrophic Lateral Sclerosis.2021Neuroscience
  19. Glutathione S-transferase Omega 2 DD genotype is associated with an increased risk of sporadic amyotrophic lateral sclerosis in Chinese men.2021The Journal of international medical research
Earlier papers (2016–2020)18
  1. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model.2020Gene therapy
  2. H63D CG genotype of HFE is associated with increased risk of sporadic amyotrophic lateral sclerosis in a single population.2020Journal of integrative neuroscience
  3. Deletion of Tbk1 disrupts autophagy and reproduces behavioral and locomotor symptoms of FTD-ALS in mice.2019Aging
  4. Evidence for a protective role of the CX3CL1/CX3CR1 axis in a model of amyotrophic lateral sclerosis.2019Biological chemistry
  5. The role of insulin-like growth factor 1 in ALS cell and mouse models: A mitochondrial protector.2019Brain research bulletin
  6. Neuroprotective Effects of Genistein in a SOD1-G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis.2019Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  7. Raloxifene, a promising estrogen replacement, limits TDP-25 cell death by enhancing autophagy and suppressing apoptosis.2018Brain research bulletin
  8. scAAV9-VEGF-165 inhibits neuroinflammatory responses and invasion of macrophages into the peripheral nervous system of ALS transgenic mice.2018Brain research bulletin
  9. Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway.2018Brain research bulletin
  10. Progressive Degeneration and Inhibition of Peripheral Nerve Regeneration in the SOD1-G93A Mouse Model of Amyotrophic Lateral Sclerosis.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  11. Effects of Ovariectomy in an hSOD1-G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS).2018Medical science monitor : international medical journal of experimental and clinical research
  12. Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase.2018Molecular neurobiology
  13. Intrathecal Injection of scAAV9-hIGF1 Prolongs the Survival of ALS Model Mice by Inhibiting the NF-kB Pathway.2018Neuroscience
  14. IGF1 affects macrophage invasion and activation and TNF-α production in the sciatic nerves of female SOD1G93A mice.2018Neuroscience letters
  15. Characterization of aromatase expression in the spinal cord of an animal model of familial ALS.2017Brain research bulletin
  16. Intrathecal Delivery of ssAAV9-DAO Extends Survival in SOD1G93A ALS Mice.2017Neurochemical research
  17. Slow Intrathecal Injection of rAAVrh10 Enhances its Transduction of Spinal Cord and Therapeutic Efficacy in a Mutant SOD1 Model of ALS.2017Neuroscience
  18. scAAV9-VEGF prolongs the survival of transgenic ALS mice by promoting activation of M2 microglia and the PI3K/Akt pathway.2016Brain research

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shijiazhuang for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01
  2. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 2 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 2.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Shijiazhuang for Fabry disease80 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 4 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 1.9%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025

2 hospitals in Shijiazhuang for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

5 hospitals in Shijiazhuang for Behçet disease139 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics
Chinese-language papers (not in the count)1
  1. [Clinical characteristics of Behçet syndrome in 45 children].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

7 hospitals in Shijiazhuang for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led2
  1. Bibliometric analysis of mucosal immunity in IgA nephropathy from 1990 to 2022.2024Immunity, inflammation and disease
  2. Clinicopathologic comparisons of IgA nephropathy and IgA vasculitis nephropathy in children: a ten-year single-center experience.2021Turkish journal of medical sciences
All its trials on ClinicalTrials.gov, any status4
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shijiazhuang for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Shijiazhuang for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Shijiazhuang for Hirschsprung disease76 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

河北医科大学第二医院

Second Hospital of Hebei Medical University

石家庄

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
second hospital of Hebei Medical University; Second Affiliated Hospital of Hebei Medical University; Second Hospital of Hebei Medical; Eastern Hospital of the Second Hospital of Hebei Medical University; Dwarkanath India Friendship Hospital

Suggest a correctionDownload the data